

Michael Van Ameringen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4482120/publications.pdf>

Version: 2024-02-01

122
papers

6,686
citations

57752

44
h-index

69246

77
g-index

140
all docs

140
docs citations

140
times ranked

6764
citing authors

#	ARTICLE	IF	CITATIONS
1	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision. <i>World Journal of Biological Psychiatry</i> , 2008, 9, 248-312.	2.6	661
2	Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i> , 2014, 14, S1.	2.6	569
3	The impact of anxiety disorders on educational achievement. <i>Journal of Anxiety Disorders</i> , 2003, 17, 561-571.	3.2	390
4	Post-Traumatic Stress Disorder in Canada. <i>CNS Neuroscience and Therapeutics</i> , 2008, 14, 171-181.	3.9	274
5	Manifesto for a European research network into Problematic Usage of the Internet. <i>European Neuropsychopharmacology</i> , 2018, 28, 1232-1246.	0.7	216
6	There is an app for that! The current state of mobile applications (apps) for DSM-5 obsessive-compulsive disorder, posttraumatic stress disorder, anxiety and mood disorders. <i>Depression and Anxiety</i> , 2017, 34, 526-539.	4.1	187
7	Relationship of social phobia with other psychiatric illness. <i>Journal of Affective Disorders</i> , 1991, 21, 93-99.	4.1	152
8	How to manage obsessive-compulsive disorder (OCD) under COVID-19: A clinician's guide from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the European College of Neuropsychopharmacology. <i>Comprehensive Psychiatry</i> , 2020, 100, 152174.	3.1	133
9	Childhood maltreatment linked to greater symptom severity and poorer quality of life and function in social anxiety disorder. <i>Depression and Anxiety</i> , 2009, 26, 1027-1032.	4.1	132
10	Quality of life and the anxiety disorders. <i>Journal of Anxiety Disorders</i> , 2003, 17, 405-426.	3.2	112
11	Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. <i>Depression and Anxiety</i> , 2006, 23, 1-5.	4.1	109
12	DSM-5 OBSESSIVE-COMPULSIVE AND RELATED DISORDERS: CLINICAL IMPLICATIONS OF NEW CRITERIA. <i>Depression and Anxiety</i> , 2014, 31, 487-493.	4.1	108
13	Comorbidity in obsessive-compulsive disorder (OCD): A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). <i>Comprehensive Psychiatry</i> , 2014, 55, 1513-1519.	3.1	105
14	Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. <i>BMC Psychiatry</i> , 2005, 5, 5.	2.6	104
15	A Randomized, Double-Blind, Placebo-Controlled Trial of Olanzapine in the Treatment of Trichotillomania. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1336-1343.	2.2	103
16	Fluoxetine efficacy in social phobia. <i>Journal of Clinical Psychiatry</i> , 1993, 54, 27-32.	2.2	102
17	A High-Risk Pilot Study of the Children of Adults with Social Phobia. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 1996, 35, 1511-1517.	0.5	95
18	Early intervention for obsessive compulsive disorder: An expert consensus statement. <i>European Neuropsychopharmacology</i> , 2019, 29, 549-565.	0.7	92

#	ARTICLE	IF	CITATIONS
19	Relationship of Childhood Sexual and Physical Abuse to Anxiety Disorders. <i>Journal of Nervous and Mental Disease</i> , 1995, 183, 309-314.	1.0	89
20	The Relationship of Behavioral Inhibition and Shyness to Anxiety Disorder. <i>Journal of Nervous and Mental Disease</i> , 1998, 186, 425-431.	1.0	88
21	The Selective GABA Reuptake Inhibitor Tiagabine for the Treatment of Generalized Anxiety Disorder. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1401-1408.	2.2	87
22	Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. <i>Journal of Affective Disorders</i> , 1996, 39, 115-121.	4.1	85
23	Anxiety, depression and stress during the COVID-19 pandemic: Results from a cross-sectional survey. <i>Journal of Psychiatric Research</i> , 2021, 137, 96-103.	3.1	85
24	Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. <i>International Clinical Psychopharmacology</i> , 2009, 24, 87-96.	1.7	82
25	WCA Recommendations for the Long-Term Treatment of Social Phobia. <i>CNS Spectrums</i> , 2003, 8, 40-52.	1.2	81
26	Overlapping patterns of recreational and medical cannabis use in a large community sample of cannabis users. <i>Comprehensive Psychiatry</i> , 2020, 102, 152188.	3.1	78
27	Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials. <i>Cognitive Behaviour Therapy</i> , 2020, 49, 1-21.	3.5	77
28	Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?. <i>Depression and Anxiety</i> , 2017, 34, 1006-1017.	4.1	73
29	Childhood attention deficit/hyperactivity disorder in adults with anxiety disorders. <i>Psychological Medicine</i> , 1999, 29, 515-525.	4.5	71
30	The Human Ortholog of Acid-Sensing Ion Channel Gene ASIC1a Is Associated With Panic Disorder and Amygdala Structure and Function. <i>Biological Psychiatry</i> , 2014, 76, 902-910.	1.3	71
31	Sertraline in social phobia. <i>Journal of Affective Disorders</i> , 1994, 31, 141-145.	4.1	70
32	Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. <i>International Clinical Psychopharmacology</i> , 2020, 35, 173-193.	1.7	70
33	Antiepileptic Drugs in the Treatment of Anxiety Disorders. <i>Drugs</i> , 2004, 64, 2199-2220.	10.9	65
34	An Open Trial of Topiramate in the Treatment of Generalized Social Phobia. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1674-1678.	2.2	62
35	“WHAT'S BUGGING THE GUT IN OCD?” A REVIEW OF THE GUT MICROBIOME IN OBSESSIVE-COMPULSIVE DISORDER. <i>Depression and Anxiety</i> , 2016, 33, 171-178.	4.1	60
36	A Double-Blind Randomized Controlled Trial of Augmentation and Switch Strategies for Refractory Social Anxiety Disorder. <i>American Journal of Psychiatry</i> , 2014, 171, 44-53.	7.2	59

#	ARTICLE	IF	CITATIONS
37	The gut microbiome and inflammation in obsessive-compulsive disorder patients compared to age- and sex-matched controls: a pilot study. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 337-347.	4.5	57
38	Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers. <i>Journal of Psychopharmacology</i> , 2014, 28, 596-602.	4.0	55
39	The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: A report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). <i>European Neuropsychopharmacology</i> , 2013, 23, 865-871.	0.7	53
40	The potential role of haloperidol in the treatment of trichotillomania. <i>Journal of Affective Disorders</i> , 1999, 56, 219-226.	4.1	50
41	Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). <i>International Journal of Psychiatry in Clinical Practice</i> , 2016, 20, 210-217.	2.4	50
42	When Too Much Is Not Enough: Obsessive-Compulsive Disorder as a Pathology of Stopping, Rather than Starting. <i>PLoS ONE</i> , 2012, 7, e30586.	2.5	49
43	The use of waitlists as control conditions in anxiety disorders research. <i>Journal of Psychiatric Research</i> , 2016, 83, 112-120.	3.1	48
44	Paroxetine in Social Phobia. <i>Journal of Clinical Psychiatry</i> , 1996, 57, 519-522.	2.2	46
45	Emerging Treatments for Child and Adolescent Social Phobia: A Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2005, 15, 589-607.	1.3	45
46	Adult Attention Deficit Hyperactivity Disorder in an Anxiety Disorders Population. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 221-226.	3.9	43
47	The psychology of potential threat: Properties of the security motivation system. <i>Biological Psychology</i> , 2010, 85, 331-337.	2.2	42
48	Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users. <i>Journal of Psychiatric Research</i> , 2019, 111, 134-139.	3.1	42
49	A PET provocation study of generalized social phobia. <i>Psychiatry Research - Neuroimaging</i> , 2004, 132, 13-18.	1.8	40
50	Frontal Brain Oscillatory Coupling in Children of Parents With Social Phobia: A Pilot Study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, 111-114.	1.8	37
51	Optimizing Treatment in Social Phobia: A Review of Treatment Resistance. <i>CNS Spectrums</i> , 2004, 9, 753-762.	1.2	36
52	The Prevalence of Migraine Headaches in an Anxiety Disorders Clinic Sample. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 76-82.	3.9	36
53	Nefazodone in Social Phobia. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 96-100.	2.2	35
54	Symptom relapse following switch from Celexa to generic citalopram: an anxiety disorders case series. <i>Journal of Psychopharmacology</i> , 2007, 21, 472-476.	4.0	33

#	ARTICLE	IF	CITATIONS
55	Influence of RGS2 on Sertraline Treatment for Social Anxiety Disorder. <i>Neuropsychopharmacology</i> , 2014, 39, 1340-1346.	5.4	33
56	Topiramate Treatment for SSRI-Induced Weight Gain in Anxiety Disorders. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 981-984.	2.2	33
57	Serotonergic agents in the treatment of social phobia in children and adolescents: A case series. , 1999, 10, 33-39.		32
58	Predictors of Response in Generalized Social Phobia. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 42-48.	1.4	32
59	The Burden of Anxiety Disorders on the Family. <i>Journal of Nervous and Mental Disease</i> , 2010, 198, 876-880.	1.0	31
60	Avoidant personality disorder in individuals with generalized social anxiety disorder: What does it add?. <i>Journal of Anxiety Disorders</i> , 2012, 26, 665-672.	3.2	31
61	Prevalence of suicide attempt and clinical characteristics of suicide attempters with obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). <i>CNS Spectrums</i> , 2018, 23, 59-66.	1.2	30
62	Biological and psychosocial predictors of anxiety worsening in the postpartum period: A longitudinal study. <i>Journal of Affective Disorders</i> , 2019, 250, 218-225.	4.1	29
63	The gut microbiome in psychiatry: A primer for clinicians. <i>Depression and Anxiety</i> , 2019, 36, 1004-1025.	4.1	27
64	Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology. <i>International Clinical Psychopharmacology</i> , 2021, 36, 61-75.	1.7	27
65	Nefazodone in the Treatment of Generalized Social Phobia. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 288-295.	2.2	27
66	A 2010 Evidence-Based Algorithm for the Pharmacotherapy of Social Anxiety Disorder. <i>Current Psychiatry Reports</i> , 2010, 12, 471-477.	4.5	25
67	AUGMENTATION STRATEGIES FOR TREATMENT-RESISTANT ANXIETY DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Depression and Anxiety</i> , 2016, 33, 728-736.	4.1	25
68	12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25â€“50â€“mg/day) versus escitalopram (10â€“20â€“mg/day) in out-patients with severe generalized anxiety disorder. <i>European Neuropsychopharmacology</i> , 2018, 28, 970-979.	0.7	25
69	Selective Serotonin Reuptake Inhibitors in the Treatment of Social Phobia. <i>CNS Drugs</i> , 1999, 11, 307-315.	5.9	22
70	Higher prevalence of irritable bowel syndrome and greater gastrointestinal symptoms in obsessive-compulsive disorder. <i>Journal of Psychiatric Research</i> , 2019, 118, 1-6.	3.1	22
71	Neuroimaging findings as predictors of treatment outcome of psychotherapy in anxiety disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 91, 60-71.	4.8	22
72	Paroxetine-induced increase in LDL cholesterol levels. <i>Journal of Psychopharmacology</i> , 2009, 23, 826-830.	4.0	21

#	ARTICLE	IF	CITATIONS
73	The role of cannabis in treating anxiety. <i>Current Opinion in Psychiatry</i> , 2020, 33, 1-7.	6.3	20
74	Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 2215-2231.	4.1	19
75	Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2012, 27, 1.	1.7	19
76	Cigarette smoking in patients with obsessive compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). <i>CNS Spectrums</i> , 2015, 20, 469-473.	1.2	18
77	N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: A case series. <i>Journal of Obsessive-Compulsive and Related Disorders</i> , 2013, 2, 48-52.	1.5	17
78	New treatment models for compulsive disorders. <i>European Neuropsychopharmacology</i> , 2016, 26, 877-884.	0.7	17
79	Does SSRI augmentation with antidepressants that influence noradrenergic function resolve depression in obsessive-compulsive disorder?. <i>Journal of Affective Disorders</i> , 2002, 68, 59-65.	4.1	16
80	Potential use of Internet-based screening for anxiety disorders: a pilot study. <i>Depression and Anxiety</i> , 2010, 27, 1006-1010.	4.1	16
81	PHARMACOTHERAPY OF SOCIAL ANXIETY DISORDER AT THE TURN OF THE MILLENNIUM. <i>Psychiatric Clinics of North America</i> , 2001, 24, 783-803.	1.3	15
82	Increased activity of frontal and limbic regions to emotional stimuli in children at-risk for anxiety disorders. <i>Psychiatry Research - Neuroimaging</i> , 2015, 233, 9-17.	1.8	14
83	Obsessive-compulsive disorder in the elderly: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). <i>European Psychiatry</i> , 2017, 45, 36-40.	0.2	13
84	Early detection and intervention for obsessive-compulsive disorder in childhood and adolescence. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 99-101.	5.6	13
85	The Impact of Changing Diagnostic Criteria in Posttraumatic Stress Disorder in a Canadian Epidemiologic Sample. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1034-1041.	2.2	13
86	Standards of care for obsessive-compulsive disorder centres. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016, 20, 204-208.	2.4	12
87	Frontal EEG alpha activity and obsessive-compulsive behaviors in non-clinical young adults: a pilot study. <i>Frontiers in Psychology</i> , 2015, 6, 1480.	2.1	11
88	The neurobiology of social phobia: From pharmacotherapy to brain imaging. <i>Current Psychiatry Reports</i> , 2000, 2, 358-366.	4.5	10
89	Lifetime bipolar disorder comorbidity and related clinical characteristics in patients with primary obsessive compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). <i>CNS Spectrums</i> , 2020, 25, 419-425.	1.2	10
90	BEHAVIORAL AND PSYCHOPHYSIOLOGICAL CHARACTERISTICS OF CHILDREN OF PARENTS WITH SOCIAL PHOBIA: A PILOT STUDY. <i>International Journal of Neuroscience</i> , 2007, 117, 605-616.	1.6	9

#	ARTICLE	IF	CITATIONS
91	Development of a Brief Version of the Social Phobia Inventory Using Item Response Theory: The Mini-SPIN-R. <i>Behavior Therapy</i> , 2013, 44, 651-661.	2.4	9
92	Obsessive-compulsive disorder during the COVID-19 pandemic. <i>Journal of Psychiatric Research</i> , 2022, 149, 114-123.	3.1	9
93	The role of gender in a large international OCD sample: A Report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) Network. <i>Comprehensive Psychiatry</i> , 2022, 116, 152315.	3.1	9
94	In the wake of a possible mistake: Security motivation, checking behavior, and OCD. <i>Journal of Behavior Therapy and Experimental Psychiatry</i> , 2015, 49, 133-140.	1.2	8
95	Placebo response in trichotillomania. <i>International Clinical Psychopharmacology</i> , 2017, 32, 350-355.	1.7	8
96	Prevalence of hoarding behaviours and excessive acquisition in users of online classified advertisements. <i>Psychiatry Research</i> , 2018, 270, 194-197.	3.3	8
97	Adverse Effects of Switching from Fluoxetine to Desipramine. <i>Canadian Journal of Psychiatry</i> , 1992, 37, 278-278.	1.9	7
98	Prevalence and correlates of current suicide risk in an international sample of OCD adults: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) network and Obsessive Compulsive and Related Disorders Network (OCRN) of the European College of Neuropsychopharmacology. <i>Journal of Psychiatric Research</i> , 2021, 140, 357-363.	3.1	7
99	Panic Attacks in Generalized Anxiety Disorder. <i>Journal of Nervous and Mental Disease</i> , 2013, 201, 52-55.	1.0	6
100	Attitudes and Beliefs Toward Cannabis Before Recreational Legalization: A Cross-Sectional Study of Community Adults in Ontario. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 526-536.	2.9	6
101	Trichotillomania in youth: a retrospective case series. <i>Depression and Anxiety</i> , 2009, 26, 661-665.	4.1	5
102	Mental health during the first wave of COVID-19 in Canada, the USA, Brazil and Italy. <i>International Journal of Psychiatry in Clinical Practice</i> , 2022, 26, 148-156.	2.4	5
103	Topiramate augmentation in a patient with obsessive-compulsive disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, E31-E32.	2.4	5
104	An Update on the Relationship Between the Gut Microbiome and Obsessive-Compulsive Disorder. <i>Psychiatric Annals</i> , 2017, 47, 542-551.	0.1	5
105	Apps for mental health. , 2022, , 395-433.		5
106	Pharmacotherapy for social anxiety disorder: an update. <i>Israel Journal of Psychiatry and Related Sciences</i> , 2009, 46, 53-61.	0.5	5
107	Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2023, 68, 299-311.	1.9	5
108	101. A pilot study of PET in social phobia. <i>Biological Psychiatry</i> , 1998, 43, S31.	1.3	4

#	ARTICLE	IF	CITATIONS
109	An evaluation of paroxetine in generalised social anxiety disorder. Expert Opinion on Pharmacotherapy, 2005, 6, 819-830.	1.8	4
110	Internet screening for anxiety disorders: Treatment-seeking outcomes in a three-month follow-up study. Psychiatry Research, 2015, 230, 689-694.	3.3	3
111	The Treatment of Refractory Generalized Anxiety Disorder. Current Treatment Options in Psychiatry, 2017, 4, 404-417.	1.9	2
112	Refractory social anxiety disorder. Journal of Psychiatry and Neuroscience, 2017, 42, E1-E2.	2.4	2
113	Influence of gender on the clinical presentation of generalized anxiety disorder, and response to treatment with Pregabalin. European Psychiatry, 2008, 23, S221-S222.	0.2	1
114	Binge eating disorder hidden behind a wall of anxiety disorders. , 2021, 46, E208-E209.		1
115	Antiepileptic Drugs in the Treatment of Anxiety Disorders: Role in Therapy. Medical Psychiatry, 2008, , 207-250.	0.2	0
116	P.4.a.006 Internet-based screening of anxiety disorders. European Neuropsychopharmacology, 2009, 19, S588-S589.	0.7	0
117	P.4.a.010 Adult attention deficit hyperactivity disorder and anxiety disorder comorbidity: prevalence in a clinical sample. European Neuropsychopharmacology, 2012, 22, S362-S363.	0.7	0
118	P.4.e.007 Internet screening for anxiety disorders and effects on treatment-seeking three months later. European Neuropsychopharmacology, 2012, 22, S376-S377.	0.7	0
119	Response to Silberman. American Journal of Psychiatry, 2014, 171, 795-796.	7.2	0
120	P.4.c.001 The use of augmentation strategies in treatment resistant anxiety disorders: a meta-analysis and systematic review. European Neuropsychopharmacology, 2014, 24, S605-S606.	0.7	0
121	Hoarding in users of online classified advertisements. European Neuropsychopharmacology, 2016, 26, S622-S623.	0.7	0
122	E.01.01 Pharmacological treatment of resistant OCD. European Neuropsychopharmacology, 2019, 29, S32.	0.7	0